PFIZi018-A
BC143c8, RCi207
iPSC line
At European Collection of Authenticated Cell Cultures (ECACC)
Timepoint: 48hr post thaw
Magnification: x4
Magnification: x4
Timepoint: 48hr post thaw
Magnification: x10
Magnification: x10
Timepoint: Confluency
Magnification: x4
Magnification: x4
Timepoint: Confluency
Magnification: x10
Magnification: x10
A CLIP contains information about a cell line including any
specific third party obligations relating to, for example,
licensing obligations or the donor consent which affect the
use of the cell line.
A batch specific Certificate of Analysis will be available to
download once you receive your EBiSC iPSC line.
General#
Cell Line |
|
| hPSCreg Name | PFIZi018-A |
| Alternative name(s) |
BC143c8, RCi207
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
|
Provider |
|
| Depositor | Pfizer Limited - Pfizer (PFIZ) |
| Distributors |
EBiSC
European Collection of Authenticated Cell Cultures (ECACC)
|
External Databases |
|
| hPSCreg | PFIZi018-A |
| BioSamples | SAMEA4458850 |
| ECACC | 66540419 |
| Cellosaurus | CVCL_RF97 |
| CLO | CLO_0101658 |
| Wikidata | Q54947273 |
General Information |
|
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
Donor Information#
General Donor Information |
|
| Sex | female |
| Age of donor (at collection) | 10-14 |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
| Disease associated phenotypes |
|
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
No
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
External Databases (Donor) |
|
| BioSamples | SAMEA4458851 |
hIPSC Derivation#
General |
|
| Source cell type |
erythroblastA nucleated precursor of an erythrocyte that lacks hematopoietic lineage markers.
|
| Age of donor (at collection) | 10-14 |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
| Genes | |
| Is reprogramming vector detectable? |
No |
| Methods used |
RT-PCR
|
Vector free reprogramming |
|
| Type of used vector free reprogramming factor(s) |
None
|
Other |
|
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions#
Latest released batch |
|
| Culture medium | Essential 8 |
| Passage method | EDTA |
| Surface coating | Matrigel / Geltrex |
| O2 concentration | 21 |
| CO2 concentration | 5 |
| Temperature | 37 |
The following are the depositor culture conditions, they do not refer to any specific batch.
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzyme-free cell dissociation
EDTA
|
| O2 Concentration | 21 % |
| CO2 Concentration | 5 % |
| Medium |
Essential 8™
|
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | No |
Characterisation#
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | FACS | Enzymatic Assay | Expression Profiles |
| TRA 1-60 |
Yes |
|
||||
| SSEA-4 |
Yes |
|
||||
| SSEA-1 |
No |
|
||||
| POU5F1 (OCT-4) |
Yes |
|
Differentiation Potency
In vitro directed differentiation
In vitro directed differentiation
In vitro directed differentiation
Microbiology / Virus Screening |
|
| HIV 1 | Negative |
| HIV 2 | Negative |
| Hepatitis B | Negative |
| Hepatitis C | Negative |
| Mycoplasma | Negative |
Sterility |
|
| Inoculation for microbiological growth | No Contaminants Detected |
| Mycoplasma | Not Detected |
| Viability | Viable post-cryopreservation |
Genotyping#
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
No autosomal or sex chromosome aneuploidies were detected
Passage number: 40
Karyotyping method:
KaryoLite BoBs
|
Other Genotyping (Cell Line) |
|